Supernus and Indivior Merger Resources

Indivior Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc. have combined in a tax-free all-stock merger of equals transaction to create a leading diversified, central nervous system (CNS) biopharmaceutical company. The transaction is expected to generate significant value for stockholders of both companies, realizing $125 million in expected annual cost synergies. The combined entity is named Supernus, Inc. and is listed on the Nasdaq Global Market under the ticker symbol “SUPN”. Jack Khattar, Supernus Pharmaceuticals’ former President and Chief Executive Officer, is serving as President, Chief Executive Officer and a member of the Board of Directors of Supernus, Inc. Tony Kingsley, a member of Indivior’s former Board of Directors, is serving as Board Chair of the combined company.

Supernus Pharmaceuticals, Inc. will now be a wholly-owned subsidiary of Supernus, Inc., formerly known as Indivior Pharmaceuticals, Inc.

For more information on the strategic rationale of the merger, please read the full press release below.